title: Druggability of the inward rectifier family: a hope for rare channelopathies?
authors.affiliation: Department of Anesthesiology, Department of Pharmacology, Vanderbilt Institute of Chemical Biology, Vanderbilt Institute for Global Health, Vanderbilt University Medical Center, 1161 21st Avenue South, Nashville, TN 37232, USA. jerod.s.denton@vanderbilt.edu.
authors.forename: Jerod S
authors.initials: JS
authors.lastname: Denton
mesh_terms: D050030:Andersen Syndrome / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism; D001477:Bartter Syndrome / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism; D053447:Channelopathies / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism; D006801:Humans; D058990:Molecular Targeted Therapy / Q000639:trends*; D009154:Mutation; D024661:Potassium Channels, Inwardly Rectifying / Q000235:genetics / Q000378:metabolism*
chemical_list: D024661:Potassium Channels, Inwardly Rectifying
keywords: arrhythmia; gating; heart; helix-bundle crossing; hypertension; hypotension; kidney; nephron; rare diseases; trafficking